← boardnext 2026-12next 2026-12-31next 2026-12-31next 2026-12-31next 2026-12-31next 2026-12-31next 2027-03-31next 2027-12-31next 2029-11
DTIL
Chongqing Precision Biotech Co., Ltddistress 6/10 · elevated risk$7.16-2%today-23% from 52w high
Neurology 3Immunology / Inflammation 1Infectious Disease 1Oncology 1
Lead: Advanced Lung Cancer · target BCMA · est. market ~$35B (approx, global)
Revenue
$11M
Liquidity
$101M
Runway
1.7 yrs
Shares 1y
+119%
Price & events
+68.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-13.9%
1W
+3.0%
1M
-2.1%
3M
+70.5%
6M
+44.9%
1Y
-28.0%
2Y
-97.7%
5Y
-97.3%
All
Overview
- Market Cap
- $184.74M
- Volume
- 10.79K
- 52 Week Range
- $3.57 – $9.28
- Total Shares
- 25.80M
- Float Shares
- 20.01M
- Short %
- 9.14%
- % Held by Insiders
- 6.44%
- % Held by Institutions
- 65.86%
- RVOL
- 0.02x
- Beta
- 1.25
Pipeline stages · 15 programs
PIC1 Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CEA-targeted CAR-T cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CD70-targeted CAR-T cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Targeted CEA CAR-T
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BCMA CAR-T cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CD19 and CD22 targeted prime CAR-T cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Anti-CD123 CAR NK cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Invivo CAR-T
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PBGENE-DMD (IV)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
1mg elsunersen, 0.5mg elsunersen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 15 programs · 5 more ▾
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PRAX-562
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
60 mg ulixacaltamide, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CD123 targeted CAR-NK cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
30mg PRAX-628
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 25 trials · 17 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | PIC1 Injection | Non-Hodgkin Lymphoma | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | CEA-targeted CAR-T cells | Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 1/2 | BCMA CAR-T cells | Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | CD70 CAR-T cells | Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer, Gynecologic Cancer | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | Targeted CEA CAR-T | Advanced Lung Cancer | — | recruiting |
Show all 25 trials · 20 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 1/2 | CD19 and CD22 targeted prime CAR-T cells | B-ALL | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 1/2 | BCMA targeted prime CAR-T cells | Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | — | recruiting |
| 2027-03-31 Estimated 50% readout ~2027-04-30 | Phase 1 | Anti-CD5 CAR NK cells | T-ALL/Lymphoma | — | recruiting |
| 2027-10-30 Estimated 50% readout ~2027-11-29 | Phase 1 | Anti-CD123 CAR NK cells | AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) | — | recruiting |
| 2027-11-01 Estimated 50% readout ~2027-12-01 | Phase 1 | MC-1-50 | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | — | not yet recruiting |
| 2027-12-31 Estimated 50% readout ~2028-01-30 | Phase 1 | Targeted CEA CAR-T | Advanced Lung Cancer | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-01-30 | Phase 1 | Invivo CAR-T | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-01-30 | Phase 1 | Targeted CEA CAR-T | Advanced Lung Cancer | — | recruiting |
| 2028-02-29 Estimated 50% readout ~2028-03-30 | Phase 1 | Targeted CEA CAR-T | Advanced Lung Cancer | — | recruiting |
| 2028-03-31 Estimated 50% readout ~2028-04-30 | Phase 1 | CEA-targeted CAR-T cells | Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer | — | recruiting |
| 2028-03-31 Estimated 50% readout ~2028-04-30 | Phase 1 | CD70-targeted CAR-T cells | Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer, Cervical Cancer, Thymic Carcinoma | — | recruiting |
| 2029-11 Estimated 50% readout ~2029-12-16 | Phase 1/2 | PBGENE-DMD (IV)fast track | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | — | recruiting |
| 2026-06 | Phase 3 | 1mg elsunersen, 0.5mg elsunersen | Epileptic Encephalopathy, SCN2A Encephalopathy | 40 | recruiting |
| 2026-03-30 | Phase 1 | BCMA/CD70-targetd CAR-T | Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome | 11 | recruiting |
| 2025-12-31 | Phase 1/2 | CD123 targeted CAR-NK cells | Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia, Refractory Leukemia | 36 | recruiting |
| 2025-12 | Phase 1 | PBGENE-HBVfast track | HEPATITIS B CHRONIC | — | recruiting |
| 2025-11-24 | Phase 2/3 | 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo | Focal Seizure | 230 | recruiting |
| 2025-11-12 | Phase 2/3 | PRAX-562 | SCN2A Encephalopathy, SCN8A Encephalopathy | 77 | active not recruiting |
| 2025-09 | Phase 3 | 60 mg ulixacaltamide, Placebo | Essential Tremor | 1000 | enrolling by invitation |
| 2025-07 | Phase 2 | 30mg PRAX-628 | Focal Onset Seizure, Primary Generalized Epilepsy | 50 | recruiting |
Catalyst news & presentations · 10
- 2026Guided 40%trial initiationsecondaryPBGENE-DMD · FUNCTION-DMD clinical trial commencedSEC 8-K
- by year end 2026Guided 40%readoutPhase 1/2PBGENE-DMD · Initial data from multiple patients expected by year end 2026SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 1/2PBGENE-DMD · Activate first clinical site in the U.S. for FUNCTION-DMD trialSEC 8-K
- first half of 2026readoutPBGENE-HBV · Additional biopsy data expected in first half of 2026SEC 8-K
- late-Q1 or early-Q2 2026trial initiationsecondaryPhase 1/2PBGENE-DMD · First patient dosing expected in late-Q1 or early-Q2 2026SEC 8-K
- 2026-02-11fda agreementPBGENE-DMD · FDA clearance of IND for PBGENE-DMD program for DMDSEC 8-K
- throughout 2025readoutPhase 1PBGENE-HBV · Antiviral efficacy data from ELIMINATE-B trial as cohorts completeSEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)PBGENE-DMD · Plan to submit IND and/or CTA for PBGENE-DMDSEC 8-K
- November 15, 2024conferencedata presentationsecondaryPhase 1PBGENE-HBV · Investor event highlighting preclinical safety data and Phase 1 plans ahead of AASLD.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $30 (+313% upside) · 5 analysts
- 2026-07-09HC Wainwright & Co.Buy
- 2026-06-09OppenheimerOutperform
- 2026-05-27HC Wainwright & Co.Buy
- 2025-05-21HC Wainwright & Co.Buy
- 2025-03-28HC Wainwright & Co.Buy
- 2025-03-19HC Wainwright & Co.Buy
Competitors — BCMA
Recent news
- 2026-07-20Lynx1 Capital discloses 5.4% Precision BioSciences (DTIL) ownership in Schedule 13G - Stock Titan
- 2026-07-17Precision BioSciences (DTIL) Price Target Increased by 19.13% to 37.06 - MSN
- 2026-07-15Trading the Move, Not the Narrative: (DTIL) Edition - Stock Traders Daily
- 2026-07-13Precision BioSciences (DTIL) Proxy filing Summary - Quartr
- 2026-07-10Precision BioSciences Grants Stock Units to New Employees Amid G - GuruFocus
- 2026-07-10Precision BioSciences (DTIL) Grants Inducement Awards to New Hir - GuruFocus
- 2026-07-10Precision BioSciences (DTIL) Short Interest & Short Float | Updated Jul 2026 $DTIL - MarketBeat
- 2026-07-10Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.